Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (102)Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Preheader (102)Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Typography
Arial
Colors
Text Analysis
Body Words131
Subject Words16
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px726 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer

Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer